LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
Armin Bender(Georg Speyer Haus), Elke Jäger(Krankenhaus Nordwest), Melina Biskamp, Sacha Gnjatic(Tisch Hospital), Julia Karbach(Memorial Sloan Kettering Cancer Center), Old Lj(Krankenhaus Nordwest), A. Knuth(University Hospital Zurich), Eric W. Hoffman(Cornell University), Dirk Jäger(Memorial Sloan Kettering Cancer Center), Antje Neumann(Krankenhaus Nordwest)
Cited by 2
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k